Loading patent…
AssigneeRoche Diagnostics Operations, Inc.
InventorsChristian Scholz, Ralf Bollhagen, Alfred Engel, Elke Faatz, Peter Schaarschmidt, Barbara Upmeier, Toralf Zarnt
Estimating the term…
The invention relates to soluble rubella E1 antigens and variants of these antigens. The antigens contain amino acids 201 to 432 or 169 to 432 and are lacking amino acids 453 to 481 as well as at least the amino acids 143 to 164. They further contain a region spanning two disulfide-bridges. The invention also relates to a recombinant DNA molecule encoding the rubella E1 antigens, the expression of rubella E1 antigens as chaperone fusion proteins and their use in a method of detecting antibodies against rubella in a sample.
A rubella E1 antigen comprising amino acids 201 to 432 with the proviso that said antigen lacks sequences corresponding to amino acids 143 to 164 and 454 to 481 of the native rubella E1 antigen and containing a first disulfide bridge formed between Cys 225 and Cys 235 (C13-C14) and a second disulfide bridge formed between only one of Cys 349 and Cys 352 (C17-C18) or Cys 368 and Cys 401 (C19-C20).
A rubella E1 antigen comprising amino acids 169 to 432 with the proviso that said antigen lacks sequences corresponding to amino acids 143 to 164 and 454 to 481 of the native rubella E1 antigen and containing a first disulfide bridge formed between Cys 176 and Cys 185 (C11-C-12) and a second disulfide bridge formed between only one of Cys 349 and Cys 352 (C17-C18) or Cys 368 and Cys 401 (C19-C20).
A composition comprising two different rubella E1 antigens, said composition comprising:
Dependencies are inferred from the claim text.